Recently, Representative John Curtis introduced new legislation called the Pediatric
Research Site Network Act aimed at closing the gaps within pediatric clinical trials.
Curtis explains that “the efficacy of pediatric clinical drug development strategies
continues to be marred by inefficiencies, delay, and exorbitant costs. Consequently,
children often endure a decade-long or longer wait to gain access to medications initially
authorized for adult use…Worse still, a staggering 60 percent of these trials stall and
nearly 40 percent result in failure.” The proposed legislation outlines a series of strategic
steps to address the problem.
